HAVEN, Conn., July 7, 2022
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing an
investigational therapy Haduvio™ (oral nalbuphine ER) for
prurigo nodularis and chronic cough in idiopathic pulmonary
fibrosis (IPF), today announced that senior management will be
attending The Twelfth London International Cough Symposium being
held in London and virtually from
July 13th –
The 12th LICS brings together clinicians and
scientists in a forum to discuss the latest research advances and
evolving ideas relating to acute and chronic cough in clinical
disease, pathophysiological mechanisms, and novel treatments for
To register for the event, please click here.
About Trevi Therapeutics,
Trevi Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of the investigational therapy Haduvio for the
treatment of prurigo nodularis and chronic cough in adults with
idiopathic pulmonary fibrosis. These conditions share a common
pathophysiology that is mediated through opioid receptors in the
central and peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
Haduvio, an investigational therapy, is an oral extended-release
(ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe.
The ĸ- and µ-opioid receptors are known to be critical mediators of
itch, cough and certain movement disorders. Nalbuphine's mechanism
of action may also mitigate the risk of abuse associated with
µ-opioid agonists because it antagonizes, or blocks, µ-opioid
receptors. Parenteral nalbuphine is not currently scheduled as a
controlled substance by the DEA in the United States or
by regulatory authorities in most
of Europe. Trevi intends to propose Haduvio as the
trade name for nalbuphine ER. Nalbuphine ER has been granted Fast
Track designation by the FDA for the proposed indication of
reduction of moderate to severe pruritus in adults with prurigo
nodularis. Its safety and efficacy have not been evaluated by any
Trevi Therapeutics, Inc.
View original content to download
SOURCE Trevi Therapeutics, Inc.